Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hybrid (BDBB) interferon-alpha: preformulation studies.

J D Allen1, D Bentley, R A Stringer

  • 1Drug Preformulation and Delivery Department, Ciba Pharmaceuticals (now Novartis Horsham Research Centre), Wimblehurst Road, Horsham, UK.

International Journal of Pharmaceutics
|September 30, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging research and practice: enhancing regulatory decisions with pragmatic clinical trials in oncology.

ESMO real world data and digital oncology·2026
Same author

Enriching African genome representation through the AGenDA project.

Nature·2026
Same author

Risky decision-making and nonsuicidal self-injury among university students: Examining the role of criticism feedback.

PloS one·2024
Same author

A pre-post trial to examine biological mechanisms of the effects of time-restricted eating on symptoms and quality of life in bipolar disorder.

BMC psychiatry·2024
Same author

Contexts of urgency may go beyond emotion.

Frontiers in psychiatry·2024
Same author

A randomized controlled trial to compare the effects of time-restricted eating versus Mediterranean diet on symptoms and quality of life in bipolar disorder.

BMC psychiatry·2024
Same journal

Copper metallodendrimers effectively deliver proapoptotic siRNA to human liver carcinoma HepG2 cells.

International journal of pharmaceutics·2026
Same journal

A styrene-maleic acid copolymer-based boron carrier for tumor-retentive boron delivery in boron neutron capture therapy.

International journal of pharmaceutics·2026
Same journal

Programmable gene modulation networks for Parkinson's disease using nanotechnology enabled CRISPR/Cas brain delivery.

International journal of pharmaceutics·2026
Same journal

Dual carboxylic ionization driven MCC/MAA/IA hydrogels for enhanced oral insulin delivery.

International journal of pharmaceutics·2026
Same journal

Artificial intelligence and CRISPR-based approaches for targeted delivery of bacteriophages.

International journal of pharmaceutics·2026
Same journal

A "three-in-one" nose-to-brain delivery strategy: intranasal vancomycin spray achieves simultaneous clearance of pneumococcal colonization, bacteremia, and meningitis.

International journal of pharmaceutics·2026
See all related articles

Recombinant hybrid interferon-alpha (IFN-alpha) stability varies with pH. Understanding degradation mechanisms at pH 4.0 and 7.6 aids in developing stable parenteral solutions.

Area of Science:

  • Biochemistry
  • Pharmaceutical Sciences
  • Protein Chemistry

Background:

  • Recombinant hybrid interferon-alpha (IFN-alpha) is a therapeutic protein susceptible to degradation.
  • Understanding solution-phase degradation is crucial for developing stable pharmaceutical formulations.

Purpose of the Study:

  • To elucidate the degradation mechanisms of recombinant hybrid IFN-alpha in solution.
  • To identify optimal conditions for enhancing the stability of IFN-alpha formulations.

Main Methods:

  • Reversed-phase high-performance liquid chromatography (RP-HPLC)
  • High-performance size-exclusion chromatography (HP-SEC)
  • Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)

Main Results:

Related Experiment Videos

  • Degradation pathways are pH-dependent.
  • At pH 4.0, degradation involves chemical transformation and self-proteolytic hydrolysis, retaining antiviral activity.
  • At pH 7.6, methionine oxidation and protein aggregation are primary degradation routes.

Conclusions:

  • Degradation mechanisms of IFN-alpha were delineated using multiple chromatographic and electrophoretic techniques.
  • Formulations at pH 7.6 and particularly pH 4.0 exhibit excellent chemical and physical stability.
  • These findings support the development of stable parenteral dosage forms for IFN-alpha.